ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Apellis Will Not Peruse Development of APL-9 for Severe COVID-19
March 10, 2021Apellis Pharmaceuticals announced the company will not pursue additional development of APL-9, an investigational targeted C3 therapy designed for acute interventions, for the treatment of severe COVID-19. -
Apellis Initiates Study of APL-9 in Patients with Severe COVID-19
June 04, 2020Apellis Pharmaceuticals announced the company has initiated a Phase 1/2 clinical study of APL-9, an investigational C3 inhibitor designed for acute interventions ...
Pharma Sources Insight January 2025
